Skip to main content

Table 6 Side-effects of first-line afatinib

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

CTCAE grade Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea, No. (%) 39 (45.9) 25 (29.4) 17 (20.0) 4 (4.7) 0
Stomatitis, No. (%) 62 (72.9) 13 (15.3) 8 (9.4) 2 (2.4) 0
Acne/rash, No. (%) 25 (29.4) 35 (41.2) 20 (23.5) 5 (5.9) 0
Paronychia, No. (%) 51 (60.0) 23 (27.1) 8 (9.4) 3 (3.5) 0
Fatigue, No. (%) 71 (83.5) 13 (15.3) 1 (1.2) 0 0
Side-effects, No (%) 17 (20.0) 59 (69.4) 9 (10.6)
  1. Abbreviations: CTCAE Common Terminology Criteria for Adverse Events